Trial Profile
A Randomized, Open Label Trial of the Safety and Efficacy of DEB025/Alisporivir in Combination With Pegylated Interferon-α2a and Ribavirin (Peg-INFα2a/RBV) and Boceprevir in Combination With Peg-INFα2a/RBV in African American Treatment-naïve Patients With Chronic Hepatitis C Genotype 1
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2017
Price :
$35
*
At a glance
- Drugs Alisporivir (Primary) ; Boceprevir (Primary) ; Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Novartis
- 04 Apr 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 20 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Feb 2012 Additional location [USA] identified as reported by ClinicalTrials.gov.